At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 499 enrolled
Drug / intervention
Pridopidine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Arm, Multicenter Study Evaluating the Efficacy and Safety of Pridopidine in Patients With Early Stage of Huntington Disease
In Brief
A Phase 3 clinical trial evaluating Pridopidine and Placebo for Huntington Disease. Completed, enrolled 499 participants across 58 sites in 11 countries.
Detailed Summary
This study will evaluate the efficacy and safety of pridopidine 45mg twice daily (BID) in patients with early stage manifest Huntington Disease (HD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuntington Disease
CountriesAustria, Canada, Czechia, France, Germany, Italy, Netherlands, Poland, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedSep 2020
Enrollment StartOct 2020
Primary CompletionMar 2023
Study CompletionMar 2024
TodayJul 2026
First PostedSep 21, 2020
Enrollment StartOct 16, 2020
Primary CompletionMar 14, 2023
Study CompletionMar 21, 2024
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 5.8 years ago
Interventions
Pridopidinedrug
Pridopidine hard gelatin capsule
Placebodrug
Pridopidine-matching placebo hard gelatin capsule